NIH dengue vaccine leaps into phase 3 studies

An investigational dengue vaccine developed by scientists at the National Institutes of Health (NIH), in Bethesda, Maryland, entered large-scale phase 3 efficacy trials in Brazil on February 22 following a small human challenge trial conducted in the US. A single dose of the dengue vaccine TV003 fully protected 21 vaccinated volunteers against infection in a virus challenge study, whereas 20 unvaccinated controls all developed an infection. “The challenge study looks very good, very promising,” says Annelies Wilder-Smith, director of the Global Health and Vaccinology Program at Lee Kong Chian School of Medicine in Singapore. But, she noted, the study size was relatively small, and only a single, attenuated challenge virus was used… Read more at Nature Biotechnology.

~ by jeffreyperkel on May 6, 2016.

%d bloggers like this: